Novel biomarkers for patient stratification in colorectal cancer: A review of definitions, emerging concepts, and data by Chand, M et al.
Published by Baishideng Publishing Group Inc
World Journal of 
Gastrointestinal Oncology
World J Gastrointest Oncol  2018 July 15; 10(7): 145-201
ISSN 1948-5204 (online)
SContents Monthly  Volume 10  Number 7  July 15, 2018
WJGO|www.wjgnet.com I July 15, 2018|Volume 10|Issue 7|
REVIEW
145	 Novel biomarkers for patient stratification in colorectal cancer: A review of definitions, emerging concepts, 
and data
Chand M, Keller DS, Mirnezami R, Bullock M, Bhangu A, Moran B, Tekkis PP, Brown G, Mirnezami A, Berho M
159	 HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer
Lote H, Valeri N, Chau I
172	 Advances in molecular, genetic and immune signatures of gastric cancer: Are we ready to apply them in 
our patients’ decision making?
Gkolfinopoulos S, Papamichael D, Papadimitriou K, Papanastasopoulos P, Vassiliou V, Kountourakis P
MINIREVIEWS
184	 Prediction of malignancy and adverse outcome of solid pseudopapillary tumor of the pancreas
You L, Yang F, Fu DL
ORIGINAL ARTICLE
              Retrospective Study
194 Atypical anastomotic malignancies of small bowel after subtotal gastrectomy with Billorth II 
gastroenterostomy for peptic ulcer: Report of three cases and review of the literature
Kotidis E, Ioannidis O, Pramateftakis MG, Christou K, Kanellos I, Tsalis K
Contents
WJGO|www.wjgnet.com II
ABOUT COVER
World Journal of Gastrointestinal Oncology
Volume 10  Number 7  July 15, 2018
Editorial Board Member of World Journal of Gastrointestinal Oncology,	Joseph Chao, 
MD, Assistant Professor, Medical Oncology and Therapeutics Research, City of Hope 
Comprehensive Cancer Center, Duarte, CA 91010, United States
World Journal of  Gastrointestinal Oncology (World J Gastrointest Oncol, WJGO, online ISSN 
1948-5204, DOI: 10.4251) is a peer-reviewed open access academic journal that aims to 
guide clinical practice and improve diagnostic and therapeutic skills of  clinicians.
WJGO covers topics concerning carcinogenesis, tumorigenesis, metastasis, diagnosis, 
prevention, prognosis, clinical manifestations, nutritional support, molecular mechanisms, 
and therapy of  benign and malignant tumors of  the digestive tract. The current columns 
of  WJGO include editorial, frontier, diagnostic advances, therapeutics advances, field of  
vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, 
clinical case conference (Clinicopathological conference), and autobiography. Priority 
publication will be given to articles concerning diagnosis and treatment of  gastrointestinal 
oncology diseases. The following aspects are covered: Clinical diagnosis, laboratory 
diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological 
diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical 
diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional 
treatment, minimally invasive therapy, and robot-assisted therapy. 
We encourage authors to submit their manuscripts to WJGO. We will give priority 
to manuscripts that are supported by major national and international foundations and 
those that are of  great clinical significance.
World Journal of  Gastrointestinal Oncology (WJGO) is now indexed in Science Citation Index 
Expanded (also known as SciSearch®), PubMed, and PubMed Central. The 2018 edition of  
Journal Citation Reports® cites the 2017 impact factor for WJGO as 3.140 (5-year impact 
factor: 3.228), ranking WJGO as 39 among 80 journals in gastroenterology and hepatology 
(quartile in category Q2), and 114 among 222 journals in oncology (quartile in category 
Q3). 
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com
PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, 
Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com
PUBLICATION DATE
July 15, 2018
COPYRIGHT
© 2018 Baishideng Publishing Group Inc. Articles 
published by this Open-Access journal are distributed 
under the terms of  the Creative Commons Attribution 
Non-commercial License, which permits use, distribu-
tion, and reproduction in any medium, provided the 
original work is properly cited, the use is non commer-
cial and is otherwise in compliance with the license.
SPECIAL STATEMENT 
All articles published in journals owned by the 
Baishideng Publishing Group (BPG) represent the 
views and opinions of  their authors, and not the views, 
opinions or policies of  the BPG, except where other-
wise explicitly indicated.
INSTRUCTIONS TO AUTHORS
http://www.wjgnet.com/bpg/gerinfo/204
ONLINE SUBMISSION 
http://www.f6publishing.com
NAME OF JOURNAL
World Journal of  Gastrointestinal Oncology
ISSN
ISSN 1948-5204 (online)
LAUNCH DATE
February 15, 2009
FREQUENCY
Monthly
EDITORIAL BOARD MEMBERS
All editorial board members resources online at http://
www.wjgnet.com/1948-5204/editorialboard.htm
EDITORIAL OFFICE
Jin-Lei Wang, Director
World Journal of  Gastrointestinal Oncology
Baishideng Publishing Group Inc
EDITORS FOR 
THIS ISSUE
Responsible Assistant Editor: Xiang Li                 Responsible Science Editor: Fang-Fang Ji
Responsible Electronic Editor: Wen-Wen Tan           Proofing Editorial Office Director: Jin-Lei Wang
Proofing Editor-in-Chief: Lian-Sheng Ma
AIM AND SCOPE
INDEXING/ABSTRACTING 
July 15, 2018|Volume 10|Issue 7|
and analysis, drafting and critical revision and editing, and final 
approval of the final version.
Conflict-of-interest statement: No potential conflicts of interest. 
No financial support.
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Manuscript source: Invited manuscript
Correspondence to: Manish Chand, FRCS (Gen Surg), 
PhD, Associate Professor, Surgeon, Consultant Colorectal 
Surgeon and Senior Lecturer, GENIE Centre, University 
College London, Charles Bell House, 43 Foley Street, London 
W1W 7TS, United Kingdom. m.chand@ucl.ac.uk 
Telephone: +44-20-34475879
Fax: +44-20-34479218
Received: March 8, 2018
Peer-review started: March 8, 2018
First decision: March 19, 2018
Revised: April 22, 2018
Accepted: June 8, 2018
Article in press: June 9, 2018
Published online: July 15, 2018 
Abstract
Colorectal cancer (CRC) treatment has become more pe-
rsonalised, incorporating a combination of the individual 
patient risk assessment, gene testing, and chemother-
Manish Chand, GENIE Centre, University College London, 
London W1W 7TS, United Kingdom
Deborah S Keller, Department of Surgery, Columbia University 
Medical Centre, New York, NY 10032, United States 
Reza Mirnezami, Department of Surgery, Imperial College 
London, London SW7 2AZ, United Kingdom 
Marc Bullock, Department of Surgery, University of Southa-
mpton, Southampton SO17 1BJ, United Kingdom
Aneel Bhangu, Department of Surgery, University of Birmi-
ngham, Birmingham B15 2QU, United Kingdom
Brendan Moran, Department of Colorectal Surgery, North Ha-
mpshire Hospital, Basingstoke RG24 7AL, United Kingdom
Paris P Tekkis, Department of Colorectal Surgery, Royal Marsden 
Hospital and Imperial College London, London SW3 6JJ, United 
Kingdom
Gina Brown, Department of Radiology, Royal Marsden Hospital 
and Imperial College London, London SW3 6JJ, United Kingdom
Alexander Mirnezami, Department of Surgical Oncology, 
University of Southampton and NIHR, Southampton SO17 1BJ, 
United Kingdom 
Mariana Berho, Department of Pathology, Cleveland Clinic 
Florida, Weston, FL 33331, United States 
ORCID number: Manish Chand (0000-0001-9086-8724); 
Deborah S Keller (0000-0002-8645-6206); Reza Mirnezami 
(0000-0003-4572-5286); Marc Bullock (0000-0002-2355-9494); 
Aneel Bhangu (0000-0001-5999-4618); Brendan Moran 
(0000-0002-9862-6241); Paris P Tekkis (0000-0002-0730-3907); 
Gina Brown (0000-0002-2336-622X); Alexander Mirnezami 
(000-0002-6199-8332); Mariana Berho (0000-0000-1111-1111).
Author contributions: All authors equally contributed to this 
paper with conception and design of the study, literature review 
145
Submit a Manuscript: http://www.f6publishing.com
DOI: 10.4251/wjgo.v10.i7.145
World J Gastrointest Oncol  2018 July 15; 10(7): 145-158
ISSN 1948-5204 (online)
July 15, 2018|Volume 10|Issue 7|WJGO|www.wjgnet.com
REVIEW
Novel biomarkers for patient stratification in colorectal 
cancer: A review of definitions, emerging concepts, and 
data 
Manish Chand, Deborah S Keller, Reza Mirnezami, Marc Bullock, Aneel Bhangu, Brendan Moran, 
Paris P Tekkis, Gina Brown, Alex Mirnezami, Mariana Berho
apy with surgery for optimal care. The improvement of 
staging with high-resolution imaging has allowed more se-
lective treatments, optimising survival outcomes. The next 
step is to identify biomarkers that can inform clinicians 
of expected prognosis and offer the most beneficial 
treatment, while reducing unnecessary morbidity for 
the patient. The search for biomarkers in CRC has be-
en of significant interest, with questions remaining on 
their impact and applicability. The study of biomarkers 
can be broadly divided into metabolic, molecular, mi-
croRNA, epithelial-to-mesenchymal-transition (EMT), 
and imaging classes. Although numerous molecules 
have claimed to impact prognosis and treatment, their 
clinical application has been limited. Furthermore, rout-
ine testing of prognostic markers with no demonstrable 
influence on response to treatment is a questionable 
practice, as it increases cost and can adversely affect 
expectations of treatment. In this review we focus on 
recent developments and emerging biomarkers with pot-
ential utility for clinical translation in CRC. We examine 
and critically appraise novel imaging and molecular-based 
approaches; evaluate the promising array of microRNAs, 
analyze metabolic profiles, and highlight key findings for 
biomarker potential in the EMT pathway.
Key words: Biomarker; Colorectal cancer; Epithelial-to-
mesenchymal-transition pathway; Molecular biomarker; 
MicroRNA; Metabolic biomarker; Imaging biomarker; 
Tumour regression grade
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Biomarkers are an emerging field that can po-
tentially guide the diagnosis, prognosis, and treatment 
course in rectal cancer. Here, the current definitions, 
classifications, recent developments and emerging bio-
markers with potential utility for clinical translation in co-
lorectal cancer are reviewed by international experts for 
a better understanding in surgery.
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INTRODUCTION
Colorectal cancer (CRC) is one of the most common 
types of cancer and cancer related deaths worldwide, 
with more than a third of the incidence involving the 
rectum[1,2]. Historically, rectal cancer was associated 
with the worst oncological outcomes[3]. The choice of tr­
eatment for rectal cancer was traditionally based upon 
the histologic type of malignancy, stage of the disease, 
the tumour­node­metastasis (TNM) staging system, 
and circumferential resection margin (CRM) status[2,4]. 
These variables provide clinical utility, help determine 
the need for neoadjuvant chemoradiotherapy (CRT) 
in patients with a threatened or involved CRM, post­
operative adjuvant treatment in stage Ⅲ disease, and 
are prognostic of oncological outcome. Nevertheless, 
they provide an incomplete picture, as many patients 
with predicted early­stage disease harbour lymph node 
and systemic micrometastases, which can ultimately 
result in local and/or distant disease recurrence. Admi­
nistration of neoadjuvant CRT is also sub­optimal as 
this treatment modality has many side effects, some of 
which are fatal, while others impair quality of life (QOL). 
Response to CRT is also unpredictable; up to 30% of pa­
tients will have a complete pathological response (pCR 
= tumour regression grade 1, TRG1), and could have 
omitted surgery altogether[5,6]. In 10% of cases however, 
no reduction in tumour volume is achieved, (tumour re­
gression grade 5, TRG5); patients get no benefit from 
CRT, but are exposed to its side effects and may also 
experience cancer progression from delay to surgery[7]. 
These observations underscore the limitations of curre­
nt methods for accurate stratification of patients with 
rectal cancer, and highlight the pressing need to ident­
ify biomarkers indicative of aggressive disease and/or 
response to CRT, in order to avoid patient under­ or 
over­treatment. 
With the advent of the “holy plane”, standards for 
utilising chemoradiation, the application of minimally in­
vasive surgery, and multidisciplinary tumour boards to 
guide care, the diagnosis, staging and management of 
rectal cancer has improved significantly in the past 25 
years[8­18]. However, considerable variation still exists in 
management and outcomes, and recurrence continues to 
be a problem, with 5­year survival rates stubbornly below 
60% in most European countries[19]. To further improve 
outcomes, there is a paradigm shift in the methods of 
diagnosis, staging, determining the patient’s prognosis, 
and developing a personalized therapeutic course using 
advances in molecular biology, genetics, biochemistry, 
imaging, and the individual patient’s personal risk ass­
essment, neoadjuvant chemoradiotherapy, and adjuvant 
chemotherapy with surgery to optimise care[20]. 
The routine evaluation of microsatellite instability 
(MSI) and KRAS/NRAS/BRAF mutational status in cli­
nical practice, for risk stratification in stage Ⅱ CRC and 
to determine the utility of monoclonal antibody­based 
adjuvant therapy, such as panitumumab or cetuximab, 
in metastatic disease, provides a clear proof­of­conce­
pt that more tailored therapeutic strategies can be tr­
anslated to improve patient care through identification 
of biomarkers with functional activity. In this review, 
we explore the recent developments and emerging 
biomarkers with potential utility for clinical translation 
in CRC. We examine and critically appraise both novel 
imaging and molecular pathology based approaches; 
evaluating the promising array of microRNAs with biom­
arker potential; examining the developing techniques 
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and studies analysing metabolic profiles, and highlight 
key findings in the biomarker potential in the epithelial-
to­mesenchymal­transition (EMT) pathway.
BIOMARKERS: TERMS OF REFERENCE, 
CONCEPTS, AND CLASSIFICATION
From the Biomarkers Definitions Working Group, the 
formal definition of a biomarker is a tumour characteristic 
that can be objectively measured and evaluated as an 
indicator(s) of normal biological or pathogenic processes, 
or pharmacologic responses to a therapeutic interventi­
on that identify increased or decreased risk of patient 
benefit or harm[21,22]. Biomarkers can take multiple for­
ms when used to detect or confirm presence of disease 
or to identify affected individuals[23]. Table 1 shows 
the categorisation of biomarkers. Most biomarkers ap­
plicable in CRC are prognostic ­ providing information 
about the likelihood of a condition, disease recurrence 
or progression; or predictive ­ providing information 
about the likelihood to respond to specific treatments. 
A cause of confusion around biomarkers has been the 
loose application of their definition and application. Di­
stinguishing between predictive and prognostic bioma­
rkers­ which may not be mutually exclusive­ has been 
another source of confusion in patient stratification and 
developing treatment strategies[23]. Another source of 
confusion is the inconsistent terminology previously 
used, restricting the scope of biomarkers to describi­
ng biological molecules or monitoring the treatment 
response. The current definition laid out by Cancer 
Research United Kingdom provides a standardised voc­
abulary for investigators, explicitly stating, “molecular, 
histologic, radiographic or physiologic characteristics 
are examples of biomarkers”[24]. With this progression, 
biomarkers may be used in a variety of situations and 
serve a number of purposes ­ as a diagnostic tool; for 
risk-stratification and staging of disease; as an estimat-
or of prognosis; and, for prediction of disease response. 
The study of such biomarkers can be broadly divided 
into metabolic; miRNA; EMT; and imaging biomarkers. 
This review describes the current status of biomarkers 
in CRC within this framework.
MOLECULAR MARKERS ASSOCIATED 
WITH CARCINOGENESIS PATHWAYS
The search for molecular markers in CRC has been of 
significant recent interest. Extensive research has reve-
aled that CRC develops through three major pathways: 
(1) chromosomal abnormalities that lead to mutations 
of oncogenes and tumour suppressor genes (classic 
pathway), characterised by the adenoma­carcinoma 
progression; (2) the microsatellite instability pathway 
that results from defects in the DNA repair system; and 
(3) the methylation pathway characterized by the epige­
netic (post cellular division) methylation of numerous 
genes (methylator pathway). Hundreds of molecules 
involved in the chromosomal instability pathway have 
been associated with prognosis, however, only 1 single 
marker­ the epidermal growth factor receptor (EGFR) 
pathway­has successfully proven clinical utility to date, 
largely due to the complexity and redundancy of cellular 
pathways, as well as the lack of therapies that can target 
the different biomarkers. 
The EGFR pathway is the most clinically relevant 
molecule involved in the chromosomal instability pa­
thway, and the EGFR serves as the main target for 
treatment in locally advanced CRC. However, this tre­
atment is only useful for patients with wild­type KRAS 
(wtKRAS)[25]. Abnormal activation of the EGFR signa­
lling pathways in CRC is mainly associated with three 
mutations in the mitogen­activated protein kinase and 
phosphatidylinositol­3­kinase (PI3K) pathways ­ KRAS, 
NRAS, and BRAF; these three mutations are reported 
to occur in more than half of all CRC cases[26]. Mutation 
of some of the components of the EGFR pathway, sp­
ecifically BRAF V600E, KRAS (exon 2, 3, 4), and NRAS 
mutation (exon 2, 3, 4) cause the malignant cells to 
become resistant to anti­EGFR therapy; thus, patients 
should not be treated with either cetuximab or pan­
itumumab. As a result, all patients with metastatic CRC 
should have investigation of KRAS/NRAS and BRAF 
mutation status prior to the start of treatment. KRAS/
NRAS and BRAF mutational status may be performed 
by a variety of techniques, detailed discussion of the 
different methodologies is out of the scope of this re­
view, however it is essential to emphasize that several 
technical factors including tissue fixation and tumour 
volume amongst others may affect the accuracy of the 
test results leading to erroneous information with the 
consequent impact on the decision making process. 
Furthermore, any tumour molecular analysis should be 
performed only by a certified laboratory that can prove 
competency and proficiency to perform testing. 
Microsatellite instability status (MSI) (high or low) 
is the primary molecular marker for stratification of st­
age Ⅱ CRC. In node negative CRC, patients that are 
MSI­high have better outcomes than MSI­low tumours; 
therefore, adjuvant chemotherapy is usually not in­
dicated in MSI­high tumours. MSI­high tumours arise 
in the setting of a defective DNA repair machinery, alt­
hough several proteins have been implicated in DNA 
repair, abnormalities in MSH2, MSH6, PMS2 and MLH1 
are the most commonly described. MSI­high tumours 
may be the result of an inherited mutation of the DNA 
repair genes (Lynch syndrome) or, more commonly, 
the abnormal epigenetic methylation of the MLH1 pr­
omoter gene (sporadic MSI­high CRC). Analysis of the 
DNA repair system may be directly investigated by the 
tissue expression of MSH2, MSH6, PMS2 and MLH1 by 
immunohistochemistry, or alternatively by determination 
of microsatellite status by PCR.
The CpG Island Methylator Phenotype (methylator) 
pathway has been associated with a constellation of 
clinical (elderly patients, female, right­sided colon tum­
ours) and histological features (poorly differentiated 
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environmental stimuli or disease[32­34]. This approach provides 
rich micromolecular data downstream of the genome and 
proteome, offering a genuine functional “snapshot” of 
system activity[33]. 
The basic concept of altered cancer metabolism is 
well described across a variety of cancer subtypes[35­38]; 
the Warburg effect[39] is central to our understanding of 
cancer metabolism and glycolytic flux forms the basis for 
[18F]­fluorodeoxyglucose enhanced positron emission 
tomography (FDG­PET) solid tumour imaging[40]. Curr­
ent and next­generation nuclear magnetic resonance 
(NMR) spectroscopy and mass spectrometry (MS)­based 
profiling platforms offer a means of interrogating the 
cancer metabolome in unprecedented detail and moving 
beyond the Warburg phenomenon to identify an ent­
irely new pool of disease­relevant biomolecular data. 
These profiling approaches are likely to have three main 
areas of application in rectal cancer phenotyping: (1) 
to identify novel metabolic fingerprints for accurate and 
ultra­fast tumour tissue diagnosis, staging and grading; 
(2) to develop metabolite­based models for prediction 
of response to chemo and/or radiotherapy; and (3) to 
devise novel next­generation targeted therapies designed 
to disrupt specific metabolic pathways implicated in rectal 
cancer. 
NMR spectroscopy techniques are highly versatile and 
have been developed and applied for metabolic profiling 
of liquid­state and solid­state systems[41,42]. The techni­
que of HR­MAS NMR has been introduced more recently 
to overcome spectral line­broadening effects seen with 
conventional NMR analysis of solids[41]. This approach all­
ows acquisition of tissue-specific high-resolution spectra, 
which in combination with chemometric data treatment 
methods have the capacity to identify novel molecular 
signatures within rectal cancer tissue[43]. Recent work 
in this area has demonstrated increased abundance of 
taurine, glycine, lactate and scyllo­inositol in cancerous 
relative to healthy rectal mucosa, with a relative reduction 
in abundance observed for lipids and glucose[44] (Figure 
2). These findings can be used to determine tissue status 
(cancerous or healthy) by entirely biochemical means, 
and have also revealed strong differences in metabolite 
profiles according to tumour stage[44]. From a pharmaco­
tumours and advanced stage disease). This pattern se­
en in approximately 15%­20% of CRCs, and involves 
atypical methylation of the mismatch repair gene MLH1. 
The precursor lesions in CIMP cancers are serrated po­
lyps, not adenomatous lesions, with the initial mutation 
occurring most often in the BRAF oncogene[27]. BRAF 
mutations transform normal mucosa to aberrant crypt 
foci, hyperplastic, or sessile serrated polyps (SSP). With 
promoter methylation, loss of p16 occurs, allowing cells 
to progress to advanced polyps[28]. Increasing activity 
leads to methylation of MLH1, silencing transcription. 
Loss of MLH1 results in MMR deficiency and the MSI­H 
CRC phenotype. This is clinically important for diagnosis 
and therapeutic planning. An estimated 85% of MMR de­
ficiency CRC is due to methylation of the MLH1 promoter 
region. BRAF can be used to distinguish between MLH1 
promoter methylation and Lynch syndrome as the cause 
of CRC. A positive BRAF mutation is associated with the 
methylator pathway, and indicates MLH1 down­regula­
tion through somatic methylation of the gene’s promoter 
region, not through a germline mutation. BRAF mutati­
ons are rare in Lynch Syndrome­related CRC. On the co­
nverse, MLH1 promotor methylation in the absence of a 
BRAF mutation is consistent with Lynch Syndrome. Figure 
1 shows a clinical algorithm for testing MMR deficiency. 
Several promising new therapies aimed at demethylation 
of genes are being developed.
METABOLIC PROFILING APPROACHES
In recent years the majority of molecular profiling ap­
proaches applied to the study of rectal cancer have 
focused on macromolecules (DNA, RNA, protein). Whi­
le these avenues of research continue to offer signifi­
cant insights into rectal cancer development and pr­
ogression[29,30], it is widely accepted that a macromolecular, 
“bottom up” view of system activity cannot provide all the 
answers to facilitate precision approaches for rectal canc­
er diagnosis, prognosis and therapeutic personalisation[31]. 
Metabonomics (metabolomics/metabolic profiling) off­
ers a dynamic “top down” view of system activity and 
is defined as the systematic, time­dependent measur­
ement of metabolic shifts occurring in response to drugs, 
WJGO|www.wjgnet.com
Table 1  Biomarker types and definitions
Biomarker type Objective
Diagnostic biomarker These aim to identify the type of cancer, e.g., PSA, CEA. They may also be used to monitor or detect disease 
recurrence
Pharmacological biomarker These are used to measure response to a specific drug treatment. They are based on accurate pharmokinetic data 
and measure treatment response in early drug trials, e.g., drug therapy to angiogenesis
Predictive biomarker These are used to identify individuals who will most likely show a survival benefit to a specific targeted treatment, 
e.g., improvement in local recurrence risk following treatment for circumferential resection margin involvement
Prognostic biomarker These indicate the progress of disease and to estimate the risk of disease recurrence for example. They are used to 
estimate survival outcome and are independent of treatment strategy, e.g., nodal disease
Risk/predisposition biomarker These aim to identify individuals who are at significant risk of developing tumours, e.g., MLH1 gene
Screening biomarker These are used to identify disease at an early stage, e.g., PSA
Surrogate response biomarker These can be used as an alternative to a clinically meaningful endpoint. Therefore there must be correlation with a 
clinical endpoint, e.g., CEA
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therapeutic perspective these discoveries offer the ch­
ance to develop novel anti­cancer agents; for example, 
taurine (2­aminoethane sulphonic acid), a common beta­
amino acid has a known role in a number of fundamental 
physiological functions including cellular osmoregulation, 
cell­membrane stabilization and protein assembly[45]. Ex­
ploiting this finding by disrupting taurine handling within 
the rectal cancer microenvironment may offer a means 
of developing next­generation targeted agents for rectal 
cancer down­staging[46]. 
Mass spectrometry approaches have shown rec­
ent promise in the development of metabolite­based 
biomarker discovery for prediction of response to che­
moradiotherapy. Crotti et al[47] described novel peptidomic 
methodology in an analysis of samples of serum collected 
pre­ and post­CRT subjected to matrix­assisted laser 
desorption/ionisation­time of flight (MALDI­TOF) mass 
spectrometry. A comparison of pre-treatment serum fin-
gerprints from responders [Mandard tumour regression 
grade (TRG) 1 and 2] and non­responders (Mandard 
TRG 3-5) identified three peptides (m/z 1082.552, m/z 
1098.537 and 1104.538) that were capable of robust cl­
ass separation. Kim and colleagues also used a MALDI­
based approach, but specifically sought to evaluate the 
abundance of low­mass ions (< m/z 1000) in serum 
samples acquired from 73 patients with locally advanced 
rectal cancer, prior to CRT[48]. A panel of nine low­mass 
ions were found to have discriminatory capacity, with hyp­
oxanthine (HX; m/z 137.08) and phosphoenolpyruvic acid 
(PEP; m/z 169.04) highlighted as the most significant. 
Lower levels of HX and higher levels of PEP were shown 
to strongly correlate with improved response to CRT (TRG 
1, 2). These studies indicate the exciting potential for the 
development of a circulating biomarker panel to predict 
chemoradiosensitivity prior to commencing therapy. 
MiRNA AND RESPONSE TO TREATMENT
MicroRNAs (miRNA) are highly conserved, short, non­
coding nucleotide segments that regulate gene expre­
ssion post­transcriptionally through repressing translation 
or targeting mRNAs for degradation[49]. miRNA genes 
account for between 2%­5% of the human genome and 
are commonly clustered within introns[50]. Each miRNA 
is estimated to interact with multiple mRNA targets and, 
as a consequence, thus, these sequences may regulate 
more than 30% of all human genes[51,52]. Oncogenes and 
tumour­suppressor genes are being discovered under 
miRNA control, with the majority of miRNA genes found 
within cancer­associated genomic regions[53,54]. In CRC, 
WJGO|www.wjgnet.com
Figure 1  High-resolution magic angle spinning nuclear magnetic resonance spectroscopy of intact rectal cancer tissue biopsies. A and B: Annotated 
representative HR-MAS NMR spectral metabolite pattern for rectal cancer (A) and healthy rectal mucosa (B); C and D: Acquired data can then be subjected to 
supervised and un-supervised multivariate analysis using PCA and PLS-DA (C) to determine metabolic processes up- and down-regulated in cancerous tissue (D) 
(original data). NMR: Nuclear magnetic resonance; PCA: Principal component analysis; PLS-DA: Partial least squares discriminant analysis.
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abnormally expressed miRNAs disrupt cellular signal 
transduction and cell survival pathways, such as Wnt/β­
catenin, EGFR, and p53, linking miRNA to known events 
in the pathway of malignant transformation[55].
Accumulating evidence suggests that miRNAs may 
also have powerful clinical applications. miRNA expre­
ssion profiles are capable of discriminating tumours 
of different developmental origin[56]. Furthermore, the 
expression of individual miRNAs may be used to predi­
ct patient survival, tumour stage, the presence of lym­
ph node metastases and the response to therapy in 
CRC[55,57,58].
Three studies have specifically examined the utility 
of miRNA expression signatures in predicting chem­
oradiotherapy response in rectal cancer[59­61]. Della Vittoria 
Scarpati et al[59] examined miRNA expression in fresh­
frozen pre­treatment tumour specimens from 38 patients 
with locally advanced (T3/T4 Node +ve) rectal cancer 
and compared miRNA profiles in patients with complete 
(Mandard TRG 1; n = 9) and incomplete (Mandard TRG 
> 1; n = 29) pathological responses to a standardised 
neoadjuvant chemoradiotherapy regime consisting of 
capecitabine, oxaliplatin and 45 Gy of pelvic conformal 
radiotherapy. Thirteen significantly differentially ex­
pressed miRNAs were subsequently validated using 
high sensitivity TaqMan® qRT­PCR, of which 2; miR­622 
and miR­630, were found to predict chemoradiotherapy 
response with 100% sensitivity and specificity[59]. 
A similar analysis of 20 patients undergoing combi­
ned radiotherapy and capecitabine/5­FU chemotherapy 
compared “responders”, namely those displaying a po­
sitive response to treatment (Mandard TRG 1 and 2) 
with “non­responders” (Mandard TRG 3­5). TaqMan Low 
Density Arrays identified a miRNA signature consisting of 
8 miRNAs capable of correctly classifying 90% (9/10) of 
responders and 90% (9/10) of non­responders[60]. 
A third study, which used formalin fixed rather than 
fresh rectal cancer specimens identified a miRNA sig­
nature consisting of just 3 miRNAs (miR­153, miR­16 
and miR­590­5p), capable of distinguishing patients with 
complete and incomplete responses to therapy, however 
the value of this data is unclear as patient demographics, 
tumour characteristics, study end­points and the neo­
adjuvant treatment strategy were not clearly described[61].
As profiling methodology and the definition of tumour 
regression vary between these 3 studies, inter­study 
comparisons are of limited value; however it is important 
to note that no overlap is observed between the miRNA 
signatures described. This suggests that an miRNA bas­
ed “therapy­response” prediction tool is some way from 
becoming a reality however; other studies have clearly 
established that miRNAs do play a role in regulating the 
tissue response to neoadjuvant therapy in CRC[62­64]. Pe­
rhaps by focusing on the contribution of miRNAs within 
the biological pathways that govern resistance and/or 
sensitivity to neo­adjuvant therapy in rectal cancer, more 
clinically pertinent data will emerge on the role of miRNA 
as a potential biomarker in cancer treatment strategies[65]. 
WJGO|www.wjgnet.com
All colorectal cancers specimens
IHC for MMR genes (MLH1, MSH2, MSH6,PMS2)
or MSI PCR
Loss of MMR gene expression No loss of MMR gene expression
Loss of MSH2, MSH6, PMS2
Confirmatory germline 
testing for all MMR genes
Loss of MLH1
Test for BRAF  mutation and/or 
MLH1 promoter hypermethylation
Wildype Positive
Confirmatory germline 
testing for all MMR genes
Unlikely lynch/
Usual care
Usual care
Figure 2  Algorithm for testing of mismatch repair genes in colorectal cancer for Lynch syndrome. MMR: Mismatch repair; MSI: Microsatellite instability.
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ials are needed for validation. 
miRNA is an alternate for liquid biopsy. miRNAs have 
features making them ideal candidates for development 
as disease­specific biomarkers, and may offer superior 
sensitivity and specificity compared with ctDNA for di­
agnosing CRC[79]. miRNAs are generally stable in blood 
and other body fluids due to their small size and their 
ability to escape from RNase­mediated degradation. mi­
RNA expression levels are different in tumour compared 
to normal colon tissues[80]. miRNA are actively secreted 
from living cells, while most ctDNA is dependent on rel­
ease from apoptotic or necrotic cells[81,82]. miRNA­based 
diagnostic markers and panels have been identified for 
early detection, risk of recurrence at the time of diagnosis, 
complement to CEA for identification of distant metas­
tasis, and stratification of patients with poor prognosis 
and greater likelihood of metastasis to the lymph nodes, 
liver, and peritoneum[80,83­88]. These miRNAs are detailed 
in Table 2. While a promising tool for “precision medicine”, 
there are limitations of circulating miRNAs as biomarkers 
in CRC. The existing studies use relatively small sam­
ple sizes, are retrospective in design, and utilized non­
standardized sampling procedures. Larger, controlled 
studies are needed in order to validate the best purific-
ation method and clinical use of circulating miRNAs in 
CRC. 
An example of a blood sample­based diagnostic bio­
marker that could make a clinical impact is methylated 
Septin 9 (mSEPT9), which is validated to distinguish CRC 
from normal blood using real­time PCR[89]. This non­
invasive, blood­based tool for CRC could improve scre­
ening and surveillance compliance over colonoscopy and 
other screening methods[90]. While monitoring of mSEPT9 
may hold promise for CRC screening, a larger study po­
pulation and more prospective studies are needed to va­
lidate mSEPT9 as a diagnostic biomarker in CRC. 
ROLE OF EPITHELIAL MESENCHYMAL 
TRANSITION IN PRODUCING 
RECTAL CANCER CELLS WITH A 
RADIORESISTANCE PHENOTYPE
EMT is a physiological process resulting in transform­
ation of stable epithelial cells into mobile mesenchymal 
cells[91]. While EMT is a normal process during human 
development, it has also been shown to occur in carcin­
ogenesis[92]. In this situation, the resulting abnormal 
mesenchymal cells, which evade the influence of normal 
cellular control mechanisms, display an aggressive and 
invasive phenotype. These cells are increasingly linked 
to formation of micro­metastases, and causation of re­
sistance to the effects of radiotherapy.
EMT cellular biology
Down­regulation of membranous E­cadherin is the cla­
ssical finding of EMT. This results in loss of intercellular 
epithelial junctional complexes, promoting migration of 
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EMERGING TECHNOLOGY, LIQUID 
BIOPSIES 
The term “liquid biopsy” in cancer arose when circulating 
tumor cells (CTC) were proposed as alternatives to co­
nventional tissue biopsy in breast cancer for prognosis 
and evaluation of treatment responses[66]. The theory 
has continued to grow experimentally and has gained 
particular traction in CRC. The clinical applications of li­
quid biopsy in CRC continue to grow, including detecting 
premalignant and early­stage cancers, identification of 
aggressive phenotypes and high­risk patients, assessing 
tumor heterogeneity, residual, and recurrent disease, 
and monitoring treatment response[67]. In colon cancers, 
liquid biopsies may hold prognostic information beyond 
the nodal status for determining whether to administer 
adjuvant chemotherapy, while in rectal cancer, liquid 
biopsy may have roles for both primary disease ev­
aluation and monitoring treatment response[68]. Possible 
sources of liquid biopsies include blood, urine, saliva, 
and stool, which contain cancer­derived subcellular co­
mponents, such as circulating tumor DNA (ctDNA) and 
circulating miRNAs.
Tumour­tissue remains the “gold standard”, but 
the advent of ctDNA analysis from blood samples has 
promise as a non­invasive biomarkers. Studies have re­
ported a direct relationship between ctDNA levels and 
tumor burden, stage, vascularity, cellular turnover, and 
response to therapy[69­71]. It can enable efficient temporal 
assessment of disease status, response to intervention, 
and early detection of recurrence superior to current 
strategies, such as CEA[72]. ctDNA can monitor and re­
cognize high­risk individuals, as the plasma tumour 
DNA levels are significantly higher in patients with incr-
eased advanced/stage Ⅳ disease, recurrence, or met­
astasis[73,74]. ctDNA may be sensitive to detect with early, 
presumably curable CRC from common mutations, which 
could have implication for diagnostic testing[75]. Meta­
analysis has demonstrated high overall sensitivity and 
specificity for detecting the KRAS oncogene mutation 
in CRC, showing it may be a viable alternative to tissue 
analysis for the detection of KRAS mutations and su­
bsequent therapeutic planning[75]. Further, comparative 
analysis between CTCs and ctDNA in metastatic CRC has 
shown strong concordance between ctDNA and tissue 
for RAS, BRAF, and ERBB2 mutations (84.6%) and gre­
ater detectability than CTCs with a smaller amount of 
blood sampling[76]. ctDNA may hold specific promise as 
a biomarker to guide therapy in post­operative locally 
advanced rectal cancer, but further studies are needed 
for validation[77]. There are limitations to ctDNA as a 
biomarker. Although ctDNA targets offer a high specific-
ity, it is scarce in circulating biofluids- representing less 
than 1% of the total circulating free DNA and may be 
inadequate as clinically applicable diagnostic biomarkers. 
The best source of ctDNA is still uncertain and the size of 
the DNA released from dead cancer cells is longer than 
that of non­neoplastic DNA[70,78]. Large scale controlled tr­
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cells[93­95]. The microRNA-200 family has been identified 
as a key post­transcriptional regulator of this proce­
ss, through its targeting of E­cadherin transcriptional 
receptors[96]. Subsequent escape from growth factor 
control, with uncontrolled proliferation, results from 
the EMT process[94,95]. An end consequence of this pa­
thway is tumour budding, defined as the presence of 
single cells or small cell clusters at the invasive front of 
tumour growth[97]. Tumour budding is highly likely to be 
associated to EMT at the poorly differentiated invasive 
front[97­100].
Current evidence
There is increasing evidence linking EMT to chemor­
esistance in ovarian, pancreatic and breast cancer cell 
lines[101­104], and in human lung cancer specimens[105]. 
Emerging evidence is also relating EMT to response 
to chemoradiotherapy in CRC. This initially arose from 
testing chemoresistance in colorectal cell lines[106­108]. 
However newer human evidence is relating EMT as an 
independent biomarker of tumour budding, lymph no­
de metastases, and radioresistance[109]. The largest of 
these demonstrated that, in 103 patients with advanced 
rectal cancer, an EMT phenotype was associated with no­
nresponse to neoadjuvant therapy and reduced cancer 
specific survival[110]. More evidence from human rectal 
cancer tissue is urgently needed to assess its potential as 
a biomarker. 
Windows for intervention 
A genetic predisposition to loss of E­cadherin and sub­
sequent EMT may be causative, meaning that pre­
treatment biopsy analysis presents a window for inte­
rvention. Radiotherapy may also be a traumatic triggering 
stimulus which forces some cells into an EMT phenotype, 
meaning other methods for patient selection may be re­
quired; overlap in causation is likely. 
EMT as a prognostic and therapeutic biomarker
The biological action of metformin down­regulates the EMT 
transcription factors and up regulations E­cadherin[110]. 
Its low toxicity profile makes it a feasible option in EMT 
prevention attempts, with subsequent improvements in 
response to neoadjuvant therapies[111,112]. Additionally, 
cyclo­oxygenase (COX) inhibitors have shown potential 
to prevent EMT by reducing vimentin expression and 
increasing cell surface E­cadherin expression in cell line 
models[113]. However, due to their serious associated ca­
rdiovascular side­effects, the particular COX agent and 
dose require optimisation before widescale use[113,114]. 
The potential role of post­transcriptional microRNA­200 re­
gulation presents a further potential therapeutic target[96].
ROLE OF IMAGING BIOMARKERS IN 
DETECTION AND MONITORING DISEASE
The concept of an imaging biomarker is relatively new, 
but one which is becoming an increasingly important 
component of many phase Ⅱ/Ⅲ clinical trials as a surr­
ogate endpoint. Imaging biomarkers may allow obje­
ctive assessment of the tumour response to therapy 
and/or non­invasively detect early disease. Currently, 
the imaging techniques that seek to quantify treatment 
response in CRC can be broadly divided into those which 
measure tumour size and those which measure tumour 
activity. Whilst size criteria are the more commonly used 
biomarkers to assess radiological response in clinical tr­
ials because of their association with survival outcomes, 
it is the functional imaging techniques which are feted 
as having the greatest potential in uncovering the und­
erlying biological processes which lead to cancer. 
Measuring changes in tumour size
Reduction in tumour size has been shown to be a useful 
biomarker[115]. This can be measured in one­, two­ or 
three­dimensions by various routine imaging techniques 
such as CT and MRI[116]. However, the two commonly 
used criteria ­ WHO[117] and RECIST[118] (Table 1); have 
contrasting characteristics, in particular in the technique 
used to measure tumour size ­ only one dimension 
using RECIST criteria. Further limitations to using size 
measurements have been deciding on what degree of 
tumour bulk reduction constitutes a significant clinical 
response. An example of this is has been shown by 
Morgan et al[119], who investigated the effect of a VEGF 
receptor inhibitor on colorectal metastases, whereby 
significant size reduction was not met with an equally 
significant overall response (< 10%). However the novel 
MRI­based tumour regression grade (mrTRG), which 
stratifies response on the degree of fibrosis visualised 
in the tumour following chemoradiotherapy, has been 
shown to be a useful clinical tool[120]. The degree of fi-
brosis seen on MRI following CRT on a scale analogous 
to histopathological tumour regression grade (TRG)[121] 
­ tumour signal that has been completely replaced by 
radiological evidence of fibrosis is defined as radiological 
WJGO|www.wjgnet.com
Table 2  Candidate liquid biopsy/circulating miRNA biomarkers[145]
Expression level Diagnostic biomarker Prognostic biomarker (malignant 
potential, tumor recurrence)
Predictive biomarker (chemosensitivity)
High miR-92a, miR-141, let-7a, miR-1229, miR-1246, 
miR-150, miR-21, miR-223, miR-23a, miR-378
miR-141, miR-320, miR-596, miR-203 miR-106a, miR-484, miR-130b
Low miR-15a, miR-103, miR-148a, miR451
Adapted from Tsutomu Kawaguchi et al. Circulating MicroRNAs: A Next-Generation Clinical Biomarker for Digestive System Cancers. Int J Mol Sci 2016; 
17: 1459.
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complete response (mrTRG1­2)[122]. These findings have 
been validated in a prospectively enrolled, multicentre 
study[123] and used to influence treatment decisions in 
particular “deferral of surgery” programs. In the above 
study, multivariate analysis showed mrTRG hazard ra­
tios (HR) were independently significant for overall and 
disease­free survival. Using fibrosis as a radiological 
feature is not limited to measuring tumour size but can 
be used to quantify other prognostic factors such as 
extramural venous invasion (EMVI), for example[120]. A 
further study using prospectively collected data on EMVI 
response to neo­adjuvant chemoradiotherapy showed 
hazard ratio of 2.37 for DFS in tumours which had un­
dergone more than 50% fibrosis of tumour signal in ex-
tramural vasculature[124]. 
Measuring tumour activity
These techniques involve analysis of images to quantify 
the functional activity of tumours. The most common 
example of this is positron emission tomograhy (PET) 
with Fluorodeoxyglucose (18­FDG), which relies on the 
principle of a differential glycolytic rate seen in tumour 
cells. Using the glucose analogue 18­FDG gives an ass­
essment of tumour metabolism[125,126] by quantification 
of standard uptake values (SUV). However as timing 
of the scans from administration of the 18­FDG and su­
bsequent clearance rates may vary between centres 
and patients, comparisons and standardisation of te­
chnique has been difficult. It is also important to note th-
at until now, there has been no validation of response.
Dynamic contrast­enhanced (DCE) CT/MRI provid­
es a detailed assessment of tumour bloodflow through 
acquisition of data as specific contrast material pass­
es through the vasculature. DCE­CT has the potential 
to identify angiogenesis and has been shown to be 
able to distinguish from diverticular disease as well as 
detect early liver metastases[127,128]. Although reports 
have identified a correlation between tumour blood 
flow, the development of metastases, and decreased 
survival outcomes[129,130], this has not been translated 
to widespread clinical application. Vascular endothelial 
growth factor (VEGF) is upregulated in up to 78% of CR-
Cs[131,132] and is a potential target for functional imaging 
techniques. Bevacizmab is an anti-VEGF-A monoclonal 
antibody and DCE­MRI has been used in rectal cancer to 
evaluate treatment response using conjugation with a 
radioclueotide[133­135]. The analysis in DCE­MRI uses two 
compartments of plasma and extravascular­extracellular 
space to compare contrast agent ­ Ktrans is the constant 
which is used to depict the bloodflow. Several studies 
have validated Ktrans with expression of growth factors, 
such as VEGF and immunohistochemical confirmation 
of vessel architecture[136­139]. Reduction in Ktrans using 
Vatalanib (tyrosine kinase inhibitor which target VEGF 
receptor­2) for metastatic CRC with liver disease have 
shown promising results in the phase Ⅰ/Ⅱ setting[119,140] 
but not been translated to survival benefit in phase Ⅲ
trials.
Diffusion weighted imaging (DWI) assesses the mo­
vement of water molecules within cells using diffusion­
weighted gradients to T2 sequences. Quantitative 
analysis is possible by calculation of the apparent diffusi­
on coefficients (ADC), which are inversely correlated 
with tumour cellularity. DWI has been effective in det­
ecting small liver metastases and differentiation from 
inflammatory lesion[141­143], as well as detecting lymph 
node metastases[144], but application has been limited to 
mainly experimental work. 
CONCLUSION
The interest in biomarkers relating to rectal cancer is 
clearly increasing. They form a new aspect of clinical 
and laboratory research which help translate these 
concepts to more meaningful applications in patient 
management. Much of the current literature is still in 
its embryonic stage, but as more results from clinical tr­
ials using biomarker endpoints and outcome measures 
become available, there will be a better understanding 
by clinicians of their potential, with possible future ap­
plication to improve the predictive and prognosis of rectal 
cancer. 
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